Drug Trial Radar · NCT01520818
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes
Last checked: Nov 20, 2026Latest source record: Jan 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
666
Actual
Start
Mar 2000
Primary completion
Apr 2001
Study completion Apr 2001
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Jan 30, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart (BIAsp) 70 and/or BIAsp 50 with biphasic human insulin (BHI) 30 treatment.
Conditions
- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart 50Drug
Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50
biphasic insulin aspart 70Drug
Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70
biphasic human insulin 30Drug
Administered subcutaneously (s.c., under the skin), twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c (glycosylated haemoglobin A1c)
Locations
77 sites in 5 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Aalst, Belgium
Novo Nordisk Investigational Site
Brussels, Belgium
Novo Nordisk Investigational Site
Brussels, Belgium
Novo Nordisk Investigational Site
Edegem, Belgium
Novo Nordisk Investigational Site
Genk, Belgium
Novo Nordisk Investigational Site
Jumet, Belgium
Novo Nordisk Investigational Site
Liège, Belgium
Novo Nordisk Investigational Site
Amiens, France
Novo Nordisk Investigational Site
Avignon, France
Novo Nordisk Investigational Site
Bagnols-sur-Cèze, France
Novo Nordisk Investigational Site
Bordeaux, France
Novo Nordisk Investigational Site
Caen, France
Novo Nordisk Investigational Site
Colmar, France
Novo Nordisk Investigational Site
Dijon, France
Novo Nordisk Investigational Site
Dommartin-lès-Toul, France
Novo Nordisk Investigational Site
Grenoble, France
Novo Nordisk Investigational Site
La Rochelle, France
Novo Nordisk Investigational Site
Le Creusot, France
Novo Nordisk Investigational Site
Lorient, France
Novo Nordisk Investigational Site
Lyon, France
Novo Nordisk Investigational Site
Mâcon, France
Novo Nordisk Investigational Site
Marseille, France
Novo Nordisk Investigational Site
Nanterre, France
Novo Nordisk Investigational Site
Narbonne, France
Novo Nordisk Investigational Site
Nevers, France
Novo Nordisk Investigational Site
Nîmes, France
Novo Nordisk Investigational Site
Orléans, France
Novo Nordisk Investigational Site
Paris, France
Novo Nordisk Investigational Site
Paris, France
Novo Nordisk Investigational Site
Reims, France
Novo Nordisk Investigational Site
Roubaix, France
Novo Nordisk Investigational Site
Saint-Etienne, France
Novo Nordisk Investigational Site
Strasbourg, France
Novo Nordisk Investigational Site
Toulouse, France
Novo Nordisk Investigational Site
Dublin, Ireland
Novo Nordisk Investigational Site
Dublin, Ireland
Novo Nordisk Investigational Site
Dublin, Ireland
Novo Nordisk Investigational Site
's-Hertogenbosch, Netherlands
Novo Nordisk Investigational Site
Alkmaar, Netherlands
Novo Nordisk Investigational Site
Amersfoort, Netherlands
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.